{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T17:51:00Z","timestamp":1773510660679,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T00:00:00Z","timestamp":1683331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T00:00:00Z","timestamp":1683331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s12328-023-01802-0","type":"journal-article","created":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T03:57:38Z","timestamp":1683345458000},"page":"588-592","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Severe skin ulcer caused by taking lenvatinib after proton beam therapy"],"prefix":"10.1007","volume":"16","author":[{"given":"Taisei","family":"Iwasa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Ogiso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Takada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Mabuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koshiro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Iwashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Ogino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahito","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,6]]},"reference":[{"key":"1802_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"1802_CR2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"PR Galle","year":"2018","unstructured":"Galle PR, Forner A, Llovet JM, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182\u2013236.","journal-title":"J Hepatol"},{"key":"1802_CR3","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.1158\/1078-0432.CCR-07-5270","volume":"14","author":"J Matsui","year":"2008","unstructured":"Matsui J, Funahashi Y, Uenaka T, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008;14:5459\u201365.","journal-title":"Clin Cancer Res"},{"key":"1802_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/638747","volume":"2014","author":"O Tohyama","year":"2014","unstructured":"Tohyama O, Matsui J, Kodama K, et al. Antitumor activity of lenvatinib (E7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014:1\u201313.","journal-title":"J Thyroid Res"},{"key":"1802_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/2045-824X-6-18","volume":"6","author":"Y Yamamoto","year":"2014","unstructured":"Yamamoto Y, Matsui J, Matsushima T, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014;6:18.","journal-title":"Vasc Cell"},{"key":"1802_CR6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. The Lancet. 2018;391:1163\u201373.","journal-title":"The Lancet"},{"key":"1802_CR7","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/hepr.13460","volume":"50","author":"T Hatanaka","year":"2010","unstructured":"Hatanaka T, Kakizaki S, Nagashima T, et al. Analyses of objective response rate, progression-free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: a multicenter retrospective study. Hepatol Res. 2010;50:382\u201395.","journal-title":"Hepatol Res"},{"key":"1802_CR8","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1159\/000507022","volume":"9","author":"S Maruta","year":"2020","unstructured":"Maruta S, Ogasawara S, Ooka Y, et al. Potential of lenvatinib for an expanded indication from the REFLECT trial in patients with advanced hepatocellular carcinoma. Liver Cancer. 2020;9:382\u201396.","journal-title":"Liver Cancer"},{"key":"1802_CR9","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.3390\/cancers12071867","volume":"12","author":"S Shimose","year":"2020","unstructured":"Shimose S, Iwamoto H, Niizeki T, et al. Clinical significance of adverse events for patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter retrospective study. Cancers (Basel). 2020;12:1867.","journal-title":"Cancers (Basel)"},{"key":"1802_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40801-020-00179-7","volume":"7","author":"T Ohki","year":"2020","unstructured":"Ohki T. Impact of adverse events on the progression-free survival of patients with advanced hepatocellular carcinoma treated with lenvatinib: a multicenter retrospective study. Drugs Real World Outcomes. 2020;7:141\u20139.","journal-title":"Drugs Real World Outcomes"},{"key":"1802_CR11","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1093\/jjco\/hyw102","volume":"46","author":"H Sakurai","year":"2016","unstructured":"Sakurai H, Ishikawa H, Okumura T. Proton beam therapy in Japan: current and future status. Jpn J Clin Oncol. 2016;46:885\u201392.","journal-title":"Jpn J Clin Oncol"},{"key":"1802_CR12","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ijrobp.2016.02.027","volume":"95","author":"DA Bush","year":"2016","unstructured":"Bush DA, Smith JC, Slater JD, et al. Randomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma: results of an interim analysis. Int J Radiat Oncol Biol Phys. 2016;95:477\u201382.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1802_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.jhep.2020.09.026","volume":"74","author":"TH Kim","year":"2021","unstructured":"Kim TH, Koh YH, Kim BH, et al. Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase III trial. J Hepatol. 2021;74:603\u201312.","journal-title":"J Hepatol"},{"key":"1802_CR14","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/0016-5085(94)90764-1","volume":"106","author":"Y Matsuzaki","year":"1994","unstructured":"Matsuzaki Y, Osuga T, Saito Y, et al. A new, effective, and safe therapeutic option using proton irradiation for hepatocellular carcinoma. Gastroenterology. 1994;106:1032\u201341.","journal-title":"Gastroenterology"},{"key":"1802_CR15","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.ijrobp.2016.02.036","volume":"95","author":"PB Romesser","year":"2016","unstructured":"Romesser PB, Cahlon O, Scher ED, et al. Proton beam reirradiation for recurrent head and neck cancer: multi-institutional report on feasibility and early outcomes. Int J Radiat Oncol. 2016;95:386\u201395.","journal-title":"Int J Radiat Oncol"},{"key":"1802_CR16","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00432-019-03096-7","volume":"146","author":"Y Sekino","year":"2020","unstructured":"Sekino Y, Okumura T, Fukumitsu N, et al. Proton beam therapy for hepatocellular carcinoma associated with inferior vena cava tumor thrombus. J Cancer Res Clin Oncol. 2020;146:711\u201320.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1802_CR17","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1002\/cncr.26134","volume":"117","author":"S Komatsu","year":"2011","unstructured":"Komatsu S, Fukumoto T, Demizu Y, et al. Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma. Cancer. 2011;117:4890\u2013904.","journal-title":"Cancer"},{"key":"1802_CR18","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/ph14010036","volume":"14","author":"T Hatanaka","year":"2021","unstructured":"Hatanaka T, Naganuma A, Kakizaki S. Lenvatinib for hepatocellular carcinoma: a literature review. Pharmaceuticals. 2021;14:36.","journal-title":"Pharmaceuticals"},{"key":"1802_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.13704","author":"M Sato-Sano","year":"2018","unstructured":"Sato-Sano M, Cury-Martins J, Macarenco R, et al. Perforating dermatosis associated with multikinase inhibitors: report of two cases, including one associated with lenvatinib. J Ger Soc Dermatol. 2018. https:\/\/doi.org\/10.1111\/ddg.13704.","journal-title":"J Ger Soc Dermatol"},{"key":"1802_CR20","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1634\/theoncologist.2011-0115","volume":"16","author":"P Gomez","year":"2011","unstructured":"Gomez P, Lacouture ME. Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. Oncologist. 2011;16:1508\u201319.","journal-title":"Oncologist"},{"key":"1802_CR21","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.anl.2016.07.016","volume":"44","author":"N Uwa","year":"2017","unstructured":"Uwa N, Terada T, Mohri T, et al. An unexpected skin ulcer and soft tissue necrosis after the nonconcurrent combination of proton beam therapy and pazopanib: a case of myxofibrosarcoma. Auris Nasus Larynx. 2017;44:484\u20138.","journal-title":"Auris Nasus Larynx"},{"key":"1802_CR22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s40792-020-00902-0","volume":"6","author":"E Higaki","year":"2020","unstructured":"Higaki E, Fukaya M, Miyata K, et al. Successful two-stage operation for esophageal necrosis due to proton beam therapy followed by sorafenib in a case of large hepatocellular carcinoma. Surg Case Rep. 2020;6:138.","journal-title":"Surg Case Rep"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-023-01802-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-023-01802-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-023-01802-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T18:36:52Z","timestamp":1689791812000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-023-01802-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,6]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1802"],"URL":"https:\/\/doi.org\/10.1007\/s12328-023-01802-0","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,6]]},"assertion":[{"value":"30 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest associated with this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}